HomeCompareMAHMF vs JNJ

MAHMF vs JNJ: Dividend Comparison 2026

MAHMF yields 0.87% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAHMF wins by $2.84M in total portfolio value
10 years
MAHMF
MAHMF
● Live price
0.87%
Share price
$33.50
Annual div
$0.29
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2.87M
Annual income
$2,346,203.74
Full MAHMF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — MAHMF vs JNJ

📍 MAHMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMAHMFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MAHMF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MAHMF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MAHMF
Annual income on $10K today (after 15% tax)
$73.58/yr
After 10yr DRIP, annual income (after tax)
$1,994,273.18/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, MAHMF beats the other by $1,990,287.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MAHMF + JNJ for your $10,000?

MAHMF: 50%JNJ: 50%
100% JNJ50/50100% MAHMF
Portfolio after 10yr
$1.45M
Annual income
$1,175,446.57/yr
Blended yield
81.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MAHMF
No analyst data
Altman Z
2.2
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MAHMF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMAHMFJNJ
Forward yield0.87%2.13%
Annual dividend / share$0.29$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%28%
Portfolio after 10y$2.87M$30.3K
Annual income after 10y$2,346,203.74$4,689.40
Total dividends collected$2.80M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MAHMF vs JNJ ($10,000, DRIP)

YearMAHMF PortfolioMAHMF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,873$173.13$10,592$272.30+$281.00MAHMF
2$11,986$351.87$11,289$357.73+$697.00MAHMF
3$13,550$725.03$12,123$472.89+$1.4KMAHMF
4$16,031$1,532.03$13,141$629.86+$2.9KMAHMF
5$20,541$3,387.83$14,408$846.81+$6.1KMAHMF
6$30,092$8,113.90$16,021$1,151.60+$14.1KMAHMF
7$54,418$22,218.67$18,122$1,588.22+$36.3KMAHMF
8$133,328$75,101.04$20,930$2,228.20+$112.4KMAHMF
9$486,594$343,932.99$24,792$3,191.91+$461.8KMAHMF
10$2,866,859$2,346,203.74$30,274$4,689.40+$2.84MMAHMF

MAHMF vs JNJ: Complete Analysis 2026

MAHMFStock

Mahindra & Mahindra Limited provides mobility products and farm solutions in India and internationally. The company operates through Automotive, Farm Equipment, Financial Services, Hospitality, Real Estate, and Others segments. It offers parts and assemblies for aerospace and defense sectors; passenger and commercial vehicles, trucks, buses, vans, cars, utility vehicles, and electric vehicles; watercrafts; motorcycles, scooters, and mopeds; construction equipment, such as backhoe loaders under the Mahindra EarthMaster brand; and road construction equipment comprising motor graders under the Mahindra RoadMaster brand. The company also provides land and naval systems, defense electronics, and security consulting services for defense industry; pre-owned car and car services; and farm equipment. In addition, it operates M2All, an e-commerce platform for various portfolio of products; approximately 100 resorts; and solar PV projects. Further, the company offers financial services comprising retail and other loans, SME finance, housing finance, mutual funds, and life and non-life insurance broking services, as well as vehicle and equipment financing; logistics services; information security and risk management, engineering consulting, and business process management consulting services; information technology services; and power backup solutions, such as diesel and gas generators. Additionally, it engages in the development, management, and operation of commercial complexes; sale of timeshare and vacation ownership; and making, processing, and trading of steel for automotive, non-automotive, and power industries. The company was incorporated in 1945 and is based in Mumbai, India.

Full MAHMF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this MAHMF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MAHMF vs SCHDMAHMF vs JEPIMAHMF vs OMAHMF vs KOMAHMF vs MAINMAHMF vs ABBVMAHMF vs MRKMAHMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.